DaVita HealthCare (DVA) Ascends But Remains Behind Market: Some Facts to Note

Company Performance - DaVita HealthCare (DVA) closed at $162.36, with a daily increase of +0.22%, underperforming the S&P 500 which gained 1.83% [1] - Over the past month, DVA shares increased by 9.78%, outperforming the Medical sector which declined by 3.48% and the S&P 500 which fell by 3.31% [1] Upcoming Earnings Report - DaVita HealthCare is expected to report an EPS of $2.21, reflecting an 18.18% increase from the same quarter last year [2] - Revenue is forecasted to be $3.25 billion, indicating a growth of 3.47% compared to the corresponding quarter of the previous year [2] Analyst Estimates - Recent changes in analyst estimates for DaVita HealthCare suggest a favorable outlook on the company's business health and profitability [3] - The Zacks Rank system, which incorporates these estimate changes, currently rates DaVita HealthCare as 1 (Strong Buy) [5] Valuation Metrics - DaVita HealthCare has a Forward P/E ratio of 14.41, which is below the industry average of 21.37, indicating it is trading at a discount [6] - The company's PEG ratio stands at 0.79, compared to the industry average of 1.88, suggesting a favorable valuation relative to expected earnings growth [7] Industry Context - The Medical - Outpatient and Home Healthcare industry, to which DaVita belongs, has a Zacks Industry Rank of 156, placing it in the bottom 38% of over 250 industries [8]